Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DBVT NASDAQ:DNLI NASDAQ:GPCR NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVTDBV Technologies$14.70-1.1%$17.14$8.51▼$26.18$870.42M-0.95260,721 shs566,171 shsDNLIDenali Therapeutics$23.29+2.5%$22.21$12.58▼$27.30$3.70B0.961.92 million shs1.61 million shsGPCRStructure Therapeutics$48.48+5.3%$44.34$15.80▼$94.90$3.27B-1.5742,786 shs915,188 shsTLXTelix Pharmaceuticals$10.46-3.4%$10.36$6.28▼$16.94$3.68B-0.31153,646 shs132,193 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVTDBV Technologies-1.08%-10.86%-9.71%-31.12%+50.15%DNLIDenali Therapeutics+2.46%-9.31%-0.85%+13.22%+56.62%GPCRStructure Therapeutics+5.32%-9.15%+7.73%-4.47%+147.35%TLXTelix Pharmaceuticals-3.42%-6.10%+5.23%-2.61%-33.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVTDBV Technologies$14.70-1.1%$17.14$8.51▼$26.18$870.42M-0.95260,721 shs566,171 shsDNLIDenali Therapeutics$23.29+2.5%$22.21$12.58▼$27.30$3.70B0.961.92 million shs1.61 million shsGPCRStructure Therapeutics$48.48+5.3%$44.34$15.80▼$94.90$3.27B-1.5742,786 shs915,188 shsTLXTelix Pharmaceuticals$10.46-3.4%$10.36$6.28▼$16.94$3.68B-0.31153,646 shs132,193 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVTDBV Technologies-1.08%-10.86%-9.71%-31.12%+50.15%DNLIDenali Therapeutics+2.46%-9.31%-0.85%+13.22%+56.62%GPCRStructure Therapeutics+5.32%-9.15%+7.73%-4.47%+147.35%TLXTelix Pharmaceuticals-3.42%-6.10%+5.23%-2.61%-33.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDBVTDBV Technologies 2.71Moderate Buy$48.50229.93% UpsideDNLIDenali Therapeutics 2.82Moderate Buy$35.0850.64% UpsideGPCRStructure Therapeutics 2.89Moderate Buy$110.55128.02% UpsideTLXTelix Pharmaceuticals 2.63Moderate Buy$20.4095.03% UpsideCurrent Analyst Ratings BreakdownLatest DBVT, TLX, DNLI, and GPCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026TLXTelix Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform7/16/2026TLXTelix Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$18.007/16/2026DNLIDenali Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $35.007/13/2026DNLIDenali Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$26.007/13/2026DNLIDenali Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$29.007/7/2026TLXTelix Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.50 ➝ $22.007/7/2026TLXTelix Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.007/6/2026TLXTelix Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$22.006/30/2026DBVTDBV Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2026DBVTDBV Technologies Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$47.00 ➝ $55.006/29/2026DBVTDBV Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDBVTDBV TechnologiesN/AN/AN/AN/A$4.20 per shareN/ADNLIDenali TherapeuticsN/AN/AN/AN/A$6.91 per shareN/AGPCRStructure TherapeuticsN/AN/AN/AN/A$24.99 per shareN/ATLXTelix Pharmaceuticals$803.79M4.42$0.04 per share256.86$1.23 per share8.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDBVTDBV Technologies-$146.95M-$3.51N/AN/AN/A-3,506.53%-122.92%-86.47%N/ADNLIDenali Therapeutics-$512.54M-$2.88N/AN/AN/AN/A-52.20%-43.86%8/10/2026 (Estimated)GPCRStructure Therapeutics-$141.20M-$0.87N/AN/AN/AN/A-24.91%-23.67%8/6/2026 (Estimated)TLXTelix Pharmaceuticals-$7.12MN/AN/A95.09N/AN/AN/AN/A8/20/2026 (Estimated)Latest DBVT, TLX, DNLI, and GPCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026DNLIDenali Therapeutics-$0.72N/AN/AN/A$2.15 millionN/A8/6/2026Q2 2026GPCRStructure Therapeutics-$0.39N/AN/AN/AN/AN/A7/16/2026Q2 2026DBVTDBV Technologies-$0.12-$0.60-$0.48-$0.60$1.03 million$0.70 million5/7/2026Q1 2026DNLIDenali Therapeutics-$0.73-$0.69+$0.04-$0.69$2.57 millionN/A5/7/2026Q1 2026GPCRStructure Therapeutics-$0.39-$0.35+$0.04-$0.35$11.11 millionN/A4/30/2026Q4 2025DBVTDBV Technologies-$0.14-$0.56-$0.42-$0.55$1.11 million$0.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDBVTDBV TechnologiesN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDBVTDBV TechnologiesN/A4.764.76DNLIDenali Therapeutics0.019.289.28GPCRStructure TherapeuticsN/A26.1626.16TLXTelix Pharmaceuticals1.081.431.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDBVTDBV Technologies71.74%DNLIDenali Therapeutics92.92%GPCRStructure Therapeutics91.78%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipDBVTDBV Technologies1.06%DNLIDenali Therapeutics12.50%GPCRStructure Therapeutics5.50%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDBVTDBV Technologies8059.21 million58.58 millionOptionableDNLIDenali Therapeutics430158.71 million138.87 millionOptionableGPCRStructure Therapeutics13671.07 million67.17 millionOptionableTLXTelix Pharmaceuticals1,184339.38 millionN/AN/ADBVT, TLX, DNLI, and GPCR HeadlinesRecent News About These CompaniesTelix Pharmaceuticals (NASDAQ:TLX) Downgraded by Royal Bank Of Canada to Sector PerformJuly 17 at 9:05 AM | marketbeat.comTelix completes Japan phase 3 enrollment for IlluccixJuly 17 at 7:07 AM | msn.comTelix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 StudyJuly 17 at 7:07 AM | aol.comATelix doses first patients in OPTIMAL e prostate cancer trialJuly 16 at 3:42 PM | msn.comTelix opens Australian first radiopharmaceutical facilityJuly 16 at 3:42 PM | msn.comTelix Pharmaceuticals Limited: First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate CancerJuly 16 at 3:42 PM | finanznachrichten.deTelix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign ManufacturingJuly 15 at 10:45 PM | taiwannews.com.twTFirst Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate CancerJuly 15 at 4:20 PM | globenewswire.comTelix Pharmaceuticals Limited (NASDAQ:TLX) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 15 at 2:14 AM | americanbankingnews.comTelix Pharmaceuticals Limited (NASDAQ:TLX) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 15 at 2:13 AM | marketbeat.comDown 9%: Is the rebound over for Telix shares?July 14, 2026 | fool.com.auPrivate Advisor Group LLC Buys 128,070 Shares of Telix Pharmaceuticals Limited $TLXJuly 12, 2026 | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - What's Next?July 10, 2026 | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Receives Outperform Rating from WedbushJuly 7, 2026 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Telix Pharmaceuticals (NASDAQ:TLX)July 7, 2026 | americanbankingnews.comFDA Alignment to Advance ProstACT Global Phase 3 TrialJuly 1, 2026 | globenewswire.comTelix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic Agents - SlideshowJuly 1, 2026 | seekingalpha.comTelix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic Agents TranscriptJune 30, 2026 | seekingalpha.comChartWatch ASX scans: Pro Medicus, Life360, Telix Pharmaceuticals, Zip Co, Global X Cybersecurity ETF, Lindian ResourcesJune 29, 2026 | msn.comTelix hosts webinar on theranostics for glioma and glioblastomaJune 23, 2026 | msn.comTelix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic DirectionsJune 22, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDBVT, TLX, DNLI, and GPCR Company DescriptionsDBV Technologies NASDAQ:DBVT$14.70 -0.16 (-1.08%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$14.76 +0.06 (+0.41%) As of 07/17/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Denali Therapeutics NASDAQ:DNLI$23.29 +0.56 (+2.46%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$23.71 +0.42 (+1.82%) As of 07/17/2026 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Structure Therapeutics NASDAQ:GPCR$48.48 +2.45 (+5.32%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$47.29 -1.19 (-2.45%) As of 07/17/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Telix Pharmaceuticals NASDAQ:TLX$10.46 -0.37 (-3.42%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$10.46 +0.00 (+0.05%) As of 07/17/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/13- 07/17 The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth Why Intuitive Surgical’s Strong Quarter Still Spooked Investors Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
